Novartis AG ADR (NVS)vsWeave Communications Inc (WEAV)
NVS
Novartis AG ADR
$140.37
-0.39%
HEALTHCARE · Cap: $260.70B
WEAV
Weave Communications Inc
$7.29
-0.55%
HEALTHCARE · Cap: $583.19M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 21892% more annual revenue ($56.69B vs $257.79M). NVS leads profitability with a 22.5% profit margin vs -8.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
WEAV
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-50.3%
Fair Value
$93.40
Current Price
$140.37
$46.97 premium
Intrinsic value data unavailable for WEAV.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
15.5% revenue growth
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -24.2% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : WEAV
The strongest argument for WEAV centers on Revenue Growth. Revenue growth of 15.5% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : WEAV
The primary concerns for WEAV are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a value stock while WEAV is a growth play — different risk/reward profiles.
WEAV carries more volatility with a beta of 1.67 — expect wider price swings.
WEAV is growing revenue faster at 15.5% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 29/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Weave Communications Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Weave Communications, Inc. provides a customer communication and interaction software platform in the United States and Canada. The company is headquartered in Lehi, Utah.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?